antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-283Research ArticleВ ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУGUIDELINES FOR PRACTITIONERSДинамика распространения резистентности к беталактамным антибиотикам среди Streptococcus pneumoniae и её клиническая значимостьDynamics of Beta-Lactams Resistance Distribution in Streptococcus pneumoniae and Its Clinical SignificanceСавиноваТ. А.SavinovaT. A.noemail@neicon.ruСидоренкоС. В.SidorenkoS. V.noemail@neicon.ruБудановС. В.BudanovS. V.noemail@neicon.ruГрудининаС. А.GrudininaS. A.noemail@neicon.ruНациональное агентство клинической фармакологии и фармации, Москва; НИИ детских инфекций, Санкт-Петербург; Научный центр экспертизы средств медицинского применения, Москва; Государственный научный центр по антибиотикам, МоскваРоссияNational Agency of Clinical Pharmacology Pharmacy, Moscow; Research Institute of Children Infections, St.Petersburg; Scientific Centre of Investigation of Medicinal Products, Moscow; National Research Centre of Antibiotics, MoscowRussian Federation201013052020551-21220Copyright © Савинова Т.А., Сидоренко С.В., Буданов С.В., Грудинина С.А., 20202020Савинова Т.А., Сидоренко С.В., Буданов С.В., Грудинина С.А.Savinova T.A., Sidorenko S.V., Budanov S.V., Grudinina S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/283ReferencesAustrian R. Pneumococcus and the Brooklyn connection. Am J Med 1999; 107: 1A: 2S-6S.Austrian R. Pneumococcus and the Brooklyn connection. Am J Med 1999; 107: 1A: 2S-6S.Metlay J. P., Hofmann J., Cetron M. S. et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 3: 520-528.Metlay J. P., Hofmann J., Cetron M. S. et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 3: 520-528.Hansmana D. B. A resistant pneumococcus. Lancet 1967; 290: 264-265.Hansmana D. B. A resistant pneumococcus. Lancet 1967; 290: 264-265.Low D. E. Changing trends in antimicrobial-resistant pneumococci: it's not all bad news. Clin Infect Dis 2005; 41: Suppl 4: S228-233.Low D. E. Changing trends in antimicrobial-resistant pneumococci: it's not all bad news. Clin Infect Dis 2005; 41: Suppl 4: S228-233.Richter S. S., Heilmann K. P., Dohrn C. L. et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009; 48: 3: 23-33.Richter S. S., Heilmann K. P., Dohrn C. L. et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009; 48: 3: 23-33.Sabuncu E., David J., Bernede-Bauduin C. et al. Significant Reduction of Antibiotic Use in the Community after a Nationwide Campaign in France, 2002-2007. PLoS Med 2009; 6: 6: e1000084.Sabuncu E., David J., Bernede-Bauduin C. et al. Significant Reduction of Antibiotic Use in the Community after a Nationwide Campaign in France, 2002-2007. PLoS Med 2009; 6: 6: e1000084.Грудинина С. А., Сидоренко С. В., Федорчук В. В. и др. Динамика распространения антибиотикорезистентности среди Streptococcus pneumoniae в Москве в период с 1998 по 2003 гг. Антибиотики и химиотер 2004; 49: 4: 25-34.Грудинина С. А., Сидоренко С. В., Федорчук В. В. и др. Динамика распространения антибиотикорезистентности среди Streptococcus pneumoniae в Москве в период с 1998 по 2003 гг. Антибиотики и химиотер 2004; 49: 4: 25-34.Tait-Kamradt A. G., Cronan M., Dougherty T. J. Comparative genome analysis of high-level penicillin resistance in Streptococcus pneumoniae. Microb Drug Resist 2009; 15: 2: 69-75.Tait-Kamradt A. G., Cronan M., Dougherty T. J. Comparative genome analysis of high-level penicillin resistance in Streptococcus pneumoniae. Microb Drug Resist 2009; 15: 2: 69-75.Stanhope M. J., Lefebure T., Walsh S. L. et al. Positive selection in penicillin-binding proteins 1a, 2b, and 2x from Streptococcus pneumoniae and its correlation with amoxicillin resistance development. Infect Genet Evol 2008; 8: 3: 331-339.Stanhope M. J., Lefebure T., Walsh S. L. et al. Positive selection in penicillin-binding proteins 1a, 2b, and 2x from Streptococcus pneumoniae and its correlation with amoxicillin resistance development. Infect Genet Evol 2008; 8: 3: 331-339.Hakenbeck R., Konig A., Kern I. et al. Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae. J Bacteriol 1998;180: 7: 1831-1840.Hakenbeck R., Konig A., Kern I. et al. Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae. J Bacteriol 1998;180: 7: 1831-1840.Pallares R., Linares J., Vadillo M. et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 8: 474-480.Pallares R., Linares J., Vadillo M. et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 8: 474-480.Leggett J. E., Fantin B., Ebert S. et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 2: 281-292.Leggett J. E., Fantin B., Ebert S. et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 2: 281-292.Drusano G. L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 4: 289-300.Drusano G. L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 4: 289-300.Craig W. A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1: 1-10.Craig W. A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1: 1-10.Craig W. A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 3: 255-259.Craig W. A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 3: 255-259.Craig W. A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 1-2: 89-96.Craig W. A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 1-2: 89-96.Leggett J. E., Ebert S., Fantin B., Craig W. A. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1990; 74: Suppl: 179-184.Leggett J. E., Ebert S., Fantin B., Craig W. A. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1990; 74: Suppl: 179-184.Turnidge J., Kahlmeter G., Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006; 12: 5: 418-425.Turnidge J., Kahlmeter G., Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006; 12: 5: 418-425.Turnidge J., Paterson D. L. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20: 3: 391-408.Turnidge J., Paterson D. L. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007; 20: 3: 391-408.Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing: Nineteenth Inform Suppl Doc M100-S19. CLSI, Wayne, PA. 2009.Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing: Nineteenth Inform Suppl Doc M100-S19. CLSI, Wayne, PA. 2009.Методические указания по определению чувствительности микроорганизмов к антибактериальным препаратам: Метод указ МУК 4 2 2004; 1890-04.Методические указания по определению чувствительности микроорганизмов к антибактериальным препаратам: Метод указ МУК 4 2 2004; 1890-04.van de Sande-Bruinsma N., Grundmann H., Verloo D. et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14: 11: 1722-1730.van de Sande-Bruinsma N., Grundmann H., Verloo D. et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14: 11: 1722-1730.
The authors declare that there are no conflicts of interest present.